tiprankstipranks
Advertisement
Advertisement

GB:AZN Stock Latest News

White House says imposing tariffs on patented pharmaceutical products
The FlyWhite House says imposing tariffs on patented pharmaceutical products
3d ago
AZN
BMY
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates
PremiumCompany Announcements
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates
4d ago
AZN
Trump Trade: President says Iran war will still take weeks
PremiumThe Fly
Trump Trade: President says Iran war will still take weeks
4d ago
AA
MT
AstraZeneca Phase III EMERALD-3 trial showed meaningful improvement in endpoint
PremiumThe Fly
AstraZeneca Phase III EMERALD-3 trial showed meaningful improvement in endpoint
4d ago
AZN
Trump administration readying new pharmaceutical tariffs, FT reports
PremiumThe Fly
Trump administration readying new pharmaceutical tariffs, FT reports
4d ago
AZN
BMY
AstraZeneca U.S. shares assumed with Buy at Goldman Sachs
PremiumThe FlyAstraZeneca U.S. shares assumed with Buy at Goldman Sachs
4d ago
AZN
AstraZeneca Reports Strong Liver Cancer Results for Imfinzi–Imjudo Combo in EMERALD-3 Trial
Premium
Company Announcements
AstraZeneca Reports Strong Liver Cancer Results for Imfinzi–Imjudo Combo in EMERALD-3 Trial
4d ago
AZN
AstraZeneca Updates Total Voting Rights and Admits Additional Shares for Employee Schemes
Premium
Company Announcements
AstraZeneca Updates Total Voting Rights and Admits Additional Shares for Employee Schemes
5d ago
AZN
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
PremiumRatings
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
5d ago
AZN
Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
PremiumThe Fly
Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
6d ago
AZN
BMY
AstraZeneca announces results of 3 trials of efzimfotase alfa
PremiumThe Fly
AstraZeneca announces results of 3 trials of efzimfotase alfa
6d ago
AZN
Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
PremiumThe Fly
Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
6d ago
AZN
BMY
AstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy
PremiumCompany AnnouncementsAstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy
6d ago
AZN
AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Guggenheim
Premium
The Fly
AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Guggenheim
7d ago
AZN
AstraZeneca’s OPTIMISE-CKD Update: What Dapagliflozin Real‑World Data Could Mean for AZN Investors
Premium
Company Announcements
AstraZeneca’s OPTIMISE-CKD Update: What Dapagliflozin Real‑World Data Could Mean for AZN Investors
10d ago
AZN
AstraZeneca Expands DNA-Repair Oncology Pipeline With New AZD4956 Combination Trial
PremiumCompany Announcements
AstraZeneca Expands DNA-Repair Oncology Pipeline With New AZD4956 Combination Trial
10d ago
AZN
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
PremiumThe Fly
Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
10d ago
U
CG
Morning Movers: AstraZeneca jumps following tozorakimab trial results
PremiumThe Fly
Morning Movers: AstraZeneca jumps following tozorakimab trial results
10d ago
AGX
AZN
De‑Risking a Multibillion-Dollar COPD Opportunity: Buy Rating on AstraZeneca Following Strong Tozorakimab Phase III Data
PremiumRatings
De‑Risking a Multibillion-Dollar COPD Opportunity: Buy Rating on AstraZeneca Following Strong Tozorakimab Phase III Data
10d ago
AZN
AstraZeneca announces tozorakimab met primary endpoint in Phase III trials
PremiumThe FlyAstraZeneca announces tozorakimab met primary endpoint in Phase III trials
10d ago
AZN
AstraZeneca: Tozorakimab Phase III Success and Pipeline Catalysts Underscore Multibillion COPD Upside and Valuation Re‑Rating Potential
Premium
Ratings
AstraZeneca: Tozorakimab Phase III Success and Pipeline Catalysts Underscore Multibillion COPD Upside and Valuation Re‑Rating Potential
10d ago
AZN
AstraZeneca’s Tozorakimab Hits Phase III COPD Goals, Strengthening Respiratory Portfolio
Premium
Company Announcements
AstraZeneca’s Tozorakimab Hits Phase III COPD Goals, Strengthening Respiratory Portfolio
10d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >